Epidemiologist

About Human Pharmaceutical Business

With global presence, Boehringer Ingelheim has industry-leading expertise in medicine research and development. We are constantly developing the next generation of medical breakthroughs and successfully delivering innovations to meet the medical needs of the patients we serve in the following key areas of interest: cardiovascular, respiratory, metabolic diseases, immunology, oncology and central nervous system. In the future, the company will launch new medicines or indications in therapeutic areas including CV & metabolism, respiratory, oncology, immunology, CNS and retinal health to meet the demand of Chinese patients.

• Develop, execute, and report non-interventional (observational) studies, including:
• Post-approval commitments/Drug Intensive monitoring from Chinese authority that use real-world evidence (RWE).
• Disease epidemiology and patient population characterization for development and marketed products, including disease incidence and prevalence, assessment of current treatment patterns, drug utilization, subgroup profiles, and unmet need.
• Comparative studies of the real-world safety, effectiveness, healthcare resource utilization, and cost for BI products compared to competitors
• Regional studies of our products using data sources from across Asia
• Contribute to the real world evidence strategy for assigned products and projects, in cooperation with local and global colleagues.

• Develop and deliver trainings about RWE and Epidemiology to various internal and external audiences.
• Provide critical review and input on:
• Non-interventional (observational) study proposals.
• Publications (internal or from the medical literature).
• Expert statements and "white papers".
• Data sources for RWE studies in China and throughout Asia.
• Other epidemiology- or RWE-related documents.
• Review, assess, and summarize medical literature (in English and Chinese) to support study development, regulatory responses, and internal decision making； Contribute to relevant sections of regulatory documents (e.g. Risk Management Plans, NDAs, BTDs, orphan disease applications).
• Work with colleagues to develop an expert network in China to support real world evidence study activities and collaborations.
• Develop and integrate regional evidence from Asia to provide support for BI products.
• Clearly communicate about the RWE/Epi group and RWE studies to various internal and external stakeholders, including multifunctional product teams, local and global management, regulators, scientific and medical societies, and others.
  

• Training in statistics/epidemiology, or a related field, with suggested alternatives as follows:
• PhD or MD/PhD in statistics/epidemiology or a related field plus minimum of two (2) years of relevant experience in the healthcare industry (Pharma/Biotech preferred) or academia OR
• Masters degree (MS/MPH/PharmD) in statistics/epidemiology from an accredited institution with minimum of 4 years of relevant experience in the healthcare industry (Pharma/Biotech preferred) or academia.
• Epidemiology methods background, statistical skills, and medical/pharmacological knowledge.

• Experience with healthcare claims and/or electronic medical record databases.
• Proficient ability to speak, read and write in English and Chinese.
• International exposure in daily business environment.
• Strong written and verbal skills and well-developed multi-cultural sensitivity.
• Proactive, responsible, and accountable.
• Able to work independently as well as in cross-functional groups.
• Recommends improvements and alternative solutions to resolve problems.
• Understanding of the drug development and commercialization process.
• Basic pharmacovigilance knowledge.
• Knowledge of, or experience with, Chinese RWE data sources.
• Familiarity with Chinese regulatory and reimbursement environment.
• Experience working with patient registry data.